Ryan Richardson’s paper describing the development of Cas9-RC, a new CRISPR agent with increased performance for knockin, is out in the October 2023 issue of The CRISPR Journal.
Not only that, but the paper got the cover! Kudos to Cheryl Brandenburg for the beautiful image of knockin neurons and astrocytes using Cas9-RC in the developing mouse brain. Congrats to the whole team for concluding this large piece of Synth Bio meets Dev Neurosci!
We would be delighted to have you try out Cas9-RC for your own knockin needs. Plasmids will become available on Addgene within the next few days!
Garrett hosts NOVA’s Halal on the Lawn, then gives a talk on the lncRNA he discovered; Andrea does supply runs, then gives a talk on multiplexing schizophrenia risk genes with CRISPR; Elise handles donation logistics, and attends both talks! And at the end of a good day’s work, the lab celebrates Alex’s birthday.
Two-out-of-two for the lab’s posters at this year’s Program in Neuroscience retreat! Colin Robertson got the “Most innovative experimental design” prize for his poster on “In Vivo Prime Editor Introduces Patient Epilepsy Mutation in the Rodent Brain to Recapitulate Seizures” and Andrea Romanowski accepted a crown and scepter for the “Rule a kingdom” prize for her poster on “Multiplexed manipulation of gene dosage of schizophrenia risk genes using Cas9 fusions changes layer position of cortical neurons”. Congrats PouLab grad students!!!
Congratulations to Philip Iffland and the Peter Crino Lab –with help from PouLab grad student Andrea Romanowski among the collaborator team– for the publication of a massive piece of work just out in Brain, spanning the fields of human genetics, cell biology, genome editing, electrophysiology, and brain development to identify the gene (NPRL3) and mechanisms that cause epilepsy in affected patients.
The lab’s first pub is a nifty piece of synth bio for genome editing the brain. Richardson et al. describe a platform to test and develop new high-precision genome editing reagents. Some of our new CRISPR fusions, like eRad18-Cas9-CtIP with linear donors, showed up to 45-times higher accuracy at point-mutation editing compared to vanilla CRISPR. Another step toward direct in vivo knockin and in situ gene therapy approaches!